Boston Children's Hospital Translational Research Program (TRP) Pappendick Family Therapeutic Acceleration Award

Final Applications Due: March 18, 2024 Funding Commences: July 1, 2024

Please submit all applications to TRP@childrens.harvard.edu.

For questions regarding these instructions, please contact the TRP (trp@childrens.harvard.edu).

- 1. **Background**: The goal of the Pappendick Family Therapeutic Acceleration Award is to facilitate investigators getting their late preclinical and early clinical phase 1 studies accomplished in order to allow investigators to more rapidly pursue their research which could ultimately impact the lives of pediatric patients suffering from serious or life-threatening diseases. The Translational Research Program (TRP) has created this new initiative to provide support to investigators in two spheres:
 - Late pre-clinical studies.
 - Early clinical phase 1 studies
- 2. Purpose of grant: The program seeks to accelerate studies with clear paths to market/IP.
- 3. **Funding details**: Funding through the Pappendick Family Award is available in the form of two-year awards with up to \$100k/year (inclusive of 20% overhead) available. The TRP anticipates awarding two awards per year.
- 4. Eligibility: Applications will be accepted from Principal Investigators (PIs) who are full-time faculty of Boston Children's Hospital. For phase 1 studies, at time of application, if not already open and accruing patients, the trial should be ready to open within the upcoming 6-months. Those studies representing translation of scientific discoveries from BCH, particularly first in human studies, or trials in which BCH is the lead site will have priority. Any IP generated is expected to remain at BCH.
- 5. **Process**: Applications will be accepted on yearly basis and will be reviewed by an external review committee consisting of translational research and clinical trial experts from outside Boston Children's Hospital as well as members of the Venture Philanthropy Network.

Review criteria: Applications will be prioritized for funding based on the review panel's evaluation of the following:

- 1. The likely impact of research on child health with a clear path to market.
- 2. The role of BCH basic/discovery and translational research in development of the research and, compelling nature of the need.
- 3. The track record of the investigative team in carrying out late preclinical and/or human early phase therapeutic and device trials.

These aspects should be covered in the application.

- 6. **Signatures**: The signature of the primary investigator (and co-investigator) is required. Additionally, the signature of the primary investigator's Department Chairman or Division Chief's signature is required.
- 7. **Full applications**: Research plan/proposal (not to exceed 5 pages, including figures but excluding references) should include a summary of the study and its goal as well as a strong justification for why funding is needed and an explanation of how this funding will accelerate the research and path to market. Proposal text must be limited to five pages (including figures but excluding references).

Additional items to be included as an appendix (not included in 5- page limit) are requested:

- IRB approval letter (if applicable)
- FDA (IND/IDE) approval (if applicable)
- Summary notes from IND/IDE Review Group (IIRG) meeting (if appropriate)
- Current (if any) funding for study
- Reviewer comments from grants that fund any part of the trial

Required format: *Full* applications must be submitted in single spaced text, one-half inch margins, and no smaller than an 11-point font. Arial or Helvetica typeface is preferred. The primary applicant's name must appear in the upper right-hand corner of each page. Standard NIH forms for abstracts, NIH biosketch, and other support may be used and may be submitted as separate files. Applications must be submitted electronically, including the letter of support from Department Chair/Division Chief.

Send a PDF file of assembled proposal to TRP@childrens.harvard.edu. Application forms (modified from PHS 398) are attached.

- 8. Letter of Support: Full applications must include a letter of support from the primary applicant's chairperson. Included in the letter of support must be a statement regarding the importance of the research to the field and priority of the trial for the department/division, including prioritization of the patient population to be enrolled in the trial. The Chairperson should affirm that the applicant will have the support of the Department/Division to carry out the proposed studies.
- 9. Composition of Research Proposal: Invited research proposals should include:
 - a. Face Page
 - b. Abstracts (scientific and lay)
 - c. Table of Contents
 - d. Detailed Budget
 - e. Budget justification
 - f. Biosketch(es) (include PI and co-investigator; NIH format)
 - g. Other support
 - h. Research Plan (5-page limit), including the following items: The role of BCH basic/discovery and translational research in development of the clinical trial, compelling nature of the need and the track record of the investigative team in carrying out human early phase therapeutic and device trials.
 - i. Literature cited
 - j. Appendix
 - IRB approval (if applicable)
 - FDA approval (if applicable)
 - Summary notes from IIRG meeting (if appropriate)
 - Current funding outline for study
 - Reviewer comments from grants that fund any part of the trial
 - Letters of support from Department/Division chairperson.
 - Letters of support collaborators or consultants are optional.

Translational Research Program

2024 Pappendick Family Therapeutic Acceleration Award

Final Application Due: March 18, 2024

- 1. <u>Title of project</u>:
- 2. Principal Investigator:
 - a. Name and Degree(s):
 - b. Position title:
 - c. Division:
 - d. Department:
 - e. Mailing address:
 - f. Email address:
 - g. Phone number:
- 3. <u>Co-Investigator</u>:
 - a. Name and Degree(s):
 - b. Position title:
 - c. Division:
 - d. Department:
 - e. Mailing address:
 - f. Email address:
 - g. Phone number:
- 4. Total costs requested:
- 5. <u>Signatures:</u> The undersigned reviewed this application for a BCH TRP research award and are familiar with the policies, terms, and conditions concerning research support and accept the obligation to comply with all such policies, terms, and conditions.
 - a. Signature of Principal Investigator:
 - b. Signature of Co-Investigator_____
 - c. Signature of Department Chairperson_____

Principal Investigator (Last, First, Middle):

Scientific Abstract: Using technical language, briefly describe the proposed project in 200 words or less.

Lay Abstract: Using <u>non-technica</u>l language, briefly describe the proposed project in 100 words or less.

TRANSLATIONAL RESEARCH PROGRAM

APPLICATION CHECKLIST

Face Page and approvals	
Abstracts: scientific and lay	
Table of Contents	
Detailed Budget	
Budget Justification	
Biographical Sketch – Principal Investigator (Not to exceed five pages)	
Other Biographical Sketches (Not to exceed five pages for each)	
Other Support	
Resources	
Research Plan	
A. Hypothesis and Specific Aims	
B. Background and Significance	
C. Preliminary Studies/Progress Report	
D. Research Design and Methods	
E. Statement of the role of BCH basic/discovery and translational research in development of the clinical trial	
F. Statement of commercialization potential (include any issues of intellectual property)	
G. Literature Cited	
H. Letter from Department of Division Chair	
I. Letters of Support (e.g., Consultants)	

A-F: not to exceed 5 pages

DETAILED BUDGE DIRECT COSTS OI		ERIOD				FROM		THRO	UGH
PERSONNEL (Applicant organization only)		TYPE	% EFFORT	INST.	DC	ULLAR AMOUN	T REQUEST	ED (omit	cents)
NAME	ROLE ON PROJECT	APPT. (months)	ON PROJ.	BASE SALARY	SA	ALARY EQUESTED	FRINGE BENEFIT	s	TOTAL
	Principal Investigator			0,12,111				0	
	SUBTOTAL	S							
CONSULTANT COSTS									
EQUIPMENT (Itemize)									
SUPPLIES (Itemize by cat	egory)								
TRAVEL									
PATIENT CARE COSTS	INPATIENT								
	OUTPATIENT								
OTHER EXPENSES (Item	ize by category)								
SUBTOTAL DIRECT	COSTS FOR INITIAL	BUDGET	PERIOD					\$	
COST SHARING	Departme	nt contributio	n (30% of tota	al)					
	TRP contr	ibution (70%	of total)						
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 10, Face Page)									
Principal Investigato	or (Last, First, Middle	·):							

Principal Investigator (Last, first, middle):

OTHER SUPPORT

Provide active support for all key personnel. Other Support includes all financial resources, whether Federal, non-Federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards. Training awards, prizes, or gifts do not need to be included.

There is no "form page" for other support. Information on other support should be provided in the *format* shown below, using continuation pages as necessary. *Include the principal investigator's name at the top and number consecutively with the rest of the application.* The sample below is intended to provide guidance regarding the type and extent of information requested. Refer to the specific instructions in Section I. For information pertaining to the use of and policy for other support, see "Policy and Additional Guidance."

Format

ACTIVE/PENDING		
Project Number (Principal Investigator)	Dates of Approved/Proposed Project	Percent Effort
Source	Annual Direct Costs	
Title of Project (or Subproject)		
/		
The major goals of this project are		
OVEDIAD (automaticad far acab individual)		

OVERLAP (summarized for each individual)

<u>ACTIVE</u>

PENDING

OVERLAP